Maintenance Zithromax without Pseudomonas??

M

mneville

Guest
Chuck- Did she start culturing Psuedomonas soon after starting Zithromax??

I realize it is used as anti-inflammatory but in Aidan's case, it always clears up the sinus infections so we are hoping to prevent them by using maintenance Zithro. But I have different opionions from different docs and don't know what to do?
Megan
 
M

mneville

Guest
Chuck- Did she start culturing Psuedomonas soon after starting Zithromax??

I realize it is used as anti-inflammatory but in Aidan's case, it always clears up the sinus infections so we are hoping to prevent them by using maintenance Zithro. But I have different opionions from different docs and don't know what to do?
Megan
 
M

mneville

Guest
Chuck- Did she start culturing Psuedomonas soon after starting Zithromax??

I realize it is used as anti-inflammatory but in Aidan's case, it always clears up the sinus infections so we are hoping to prevent them by using maintenance Zithro. But I have different opionions from different docs and don't know what to do?
Megan
 
M

mneville

Guest
Chuck- Did she start culturing Psuedomonas soon after starting Zithromax??

I realize it is used as anti-inflammatory but in Aidan's case, it always clears up the sinus infections so we are hoping to prevent them by using maintenance Zithro. But I have different opionions from different docs and don't know what to do?
Megan
 
M

mneville

Guest
Chuck- Did she start culturing Psuedomonas soon after starting Zithromax??
<br />
<br />I realize it is used as anti-inflammatory but in Aidan's case, it always clears up the sinus infections so we are hoping to prevent them by using maintenance Zithro. But I have different opionions from different docs and don't know what to do?
<br />Megan
 
R

Ratatosk

Administrator
Staff member
DS was put on it as a maintenance med when he was about 2 1/2. Doctor mentioned it was to help reduce inflammation; however, he thought it would take care of the H. Flu that he always seemed to culture, which it did.
 
R

Ratatosk

Administrator
Staff member
DS was put on it as a maintenance med when he was about 2 1/2. Doctor mentioned it was to help reduce inflammation; however, he thought it would take care of the H. Flu that he always seemed to culture, which it did.
 
R

Ratatosk

Administrator
Staff member
DS was put on it as a maintenance med when he was about 2 1/2. Doctor mentioned it was to help reduce inflammation; however, he thought it would take care of the H. Flu that he always seemed to culture, which it did.
 
R

Ratatosk

Administrator
Staff member
DS was put on it as a maintenance med when he was about 2 1/2. Doctor mentioned it was to help reduce inflammation; however, he thought it would take care of the H. Flu that he always seemed to culture, which it did.
 
R

Ratatosk

Administrator
Staff member
DS was put on it as a maintenance med when he was about 2 1/2. Doctor mentioned it was to help reduce inflammation; however, he thought it would take care of the H. Flu that he always seemed to culture, which it did.
 
L

Lastar1

New member
Just wanted to post this article here. You may want to discuss this with you doctor. This study found that in patients with staph A who were put on Zithro the Staph A became MRSA in 100% of patients.

I understand the frustration with the sinus problems. My son also cultures Staph A in his sinus and even after sinus surgery he keeps having flare-ups.

Take Care,

Lisa, mom to 7 yr old w/cf

Maintenance Azithromycin Treatment in Pediatric Patients With Cystic Fibrosis: Long-Term Outcomes Related to Macrolide Resistance and Pulmonary Function.

Original Studies

Pediatric Infectious Disease Journal. 26(1):8-12, January 2007.
Tramper-Stranders, Gerdien A. MD *; Wolfs, Tom F. W. MD, PhD +; Fleer, Andre MD, PhD ++; Kimpen, Jan L. L. MD, PhD +; van der Ent, Cornelis K. MD, PhD *
Abstract:
Background: Maintenance azithromycin therapy may improve pulmonary function in patients with cystic fibrosis (CF) with Pseudomonas aeruginosa infection because of its antiinflammatory properties. However, azithromycin therapy might increase macrolide resistance in Staphylococcus aureus cultured from respiratory secretions. We studied the emergence of macrolide resistance in S. aureus and correlated this to pulmonary function decline in pediatric patients with CF on daily azithromycin therapy.

Methods: Respiratory cultures of 100 patients with CF were analyzed for S. aureus colonization and its resistance pattern before and during 3 years after initiation of azithromycin maintenance therapy. Mean annual change in forced expiratory volume as percent of predicted (FEV1 %) was calculated to compare pulmonary function before and after azithromycin therapy.

Results: Staphylococcal colonization did not significantly decrease after initiation of azithromycin (50% versus 48%). Before start of therapy, 10% of patients with staphylococcal colonization had macrolide-resistant strains. Staphylococcal resistance increased to 83% in the first year; 97% in the second and 100% in the third year after initiation of azithromycin therapy (P < 0.001). Half of macrolide-resistant S. aureus comprised the macrolide-lincosamide-streptogramin phenotype. Percent forced expiratory volume in 1 second improved in the first year after initiation of azithromycin (mean annual change: -4.75% before versus +3.09% after initiation; P < 0.01) but decreased during the second and third years after initiation (-5.15% and -3.65%, respectively). Emergence of macrolide-resistant S. aureus was not related to pulmonary function decline.

Conclusion: Maintenance azithromycin therapy in patients with CF leads to macrolide resistance in nearly all S. aureus carriers. Pulmonary function improvement after initiation of azithromycin therapy seems to be temporary and appears not to be related to macrolide resistance of S. aureus.

(C) 2007 Lippincott Williams & Wilkins, Inc.
 
L

Lastar1

New member
Just wanted to post this article here. You may want to discuss this with you doctor. This study found that in patients with staph A who were put on Zithro the Staph A became MRSA in 100% of patients.

I understand the frustration with the sinus problems. My son also cultures Staph A in his sinus and even after sinus surgery he keeps having flare-ups.

Take Care,

Lisa, mom to 7 yr old w/cf

Maintenance Azithromycin Treatment in Pediatric Patients With Cystic Fibrosis: Long-Term Outcomes Related to Macrolide Resistance and Pulmonary Function.

Original Studies

Pediatric Infectious Disease Journal. 26(1):8-12, January 2007.
Tramper-Stranders, Gerdien A. MD *; Wolfs, Tom F. W. MD, PhD +; Fleer, Andre MD, PhD ++; Kimpen, Jan L. L. MD, PhD +; van der Ent, Cornelis K. MD, PhD *
Abstract:
Background: Maintenance azithromycin therapy may improve pulmonary function in patients with cystic fibrosis (CF) with Pseudomonas aeruginosa infection because of its antiinflammatory properties. However, azithromycin therapy might increase macrolide resistance in Staphylococcus aureus cultured from respiratory secretions. We studied the emergence of macrolide resistance in S. aureus and correlated this to pulmonary function decline in pediatric patients with CF on daily azithromycin therapy.

Methods: Respiratory cultures of 100 patients with CF were analyzed for S. aureus colonization and its resistance pattern before and during 3 years after initiation of azithromycin maintenance therapy. Mean annual change in forced expiratory volume as percent of predicted (FEV1 %) was calculated to compare pulmonary function before and after azithromycin therapy.

Results: Staphylococcal colonization did not significantly decrease after initiation of azithromycin (50% versus 48%). Before start of therapy, 10% of patients with staphylococcal colonization had macrolide-resistant strains. Staphylococcal resistance increased to 83% in the first year; 97% in the second and 100% in the third year after initiation of azithromycin therapy (P < 0.001). Half of macrolide-resistant S. aureus comprised the macrolide-lincosamide-streptogramin phenotype. Percent forced expiratory volume in 1 second improved in the first year after initiation of azithromycin (mean annual change: -4.75% before versus +3.09% after initiation; P < 0.01) but decreased during the second and third years after initiation (-5.15% and -3.65%, respectively). Emergence of macrolide-resistant S. aureus was not related to pulmonary function decline.

Conclusion: Maintenance azithromycin therapy in patients with CF leads to macrolide resistance in nearly all S. aureus carriers. Pulmonary function improvement after initiation of azithromycin therapy seems to be temporary and appears not to be related to macrolide resistance of S. aureus.

(C) 2007 Lippincott Williams & Wilkins, Inc.
 
L

Lastar1

New member
Just wanted to post this article here. You may want to discuss this with you doctor. This study found that in patients with staph A who were put on Zithro the Staph A became MRSA in 100% of patients.

I understand the frustration with the sinus problems. My son also cultures Staph A in his sinus and even after sinus surgery he keeps having flare-ups.

Take Care,

Lisa, mom to 7 yr old w/cf

Maintenance Azithromycin Treatment in Pediatric Patients With Cystic Fibrosis: Long-Term Outcomes Related to Macrolide Resistance and Pulmonary Function.

Original Studies

Pediatric Infectious Disease Journal. 26(1):8-12, January 2007.
Tramper-Stranders, Gerdien A. MD *; Wolfs, Tom F. W. MD, PhD +; Fleer, Andre MD, PhD ++; Kimpen, Jan L. L. MD, PhD +; van der Ent, Cornelis K. MD, PhD *
Abstract:
Background: Maintenance azithromycin therapy may improve pulmonary function in patients with cystic fibrosis (CF) with Pseudomonas aeruginosa infection because of its antiinflammatory properties. However, azithromycin therapy might increase macrolide resistance in Staphylococcus aureus cultured from respiratory secretions. We studied the emergence of macrolide resistance in S. aureus and correlated this to pulmonary function decline in pediatric patients with CF on daily azithromycin therapy.

Methods: Respiratory cultures of 100 patients with CF were analyzed for S. aureus colonization and its resistance pattern before and during 3 years after initiation of azithromycin maintenance therapy. Mean annual change in forced expiratory volume as percent of predicted (FEV1 %) was calculated to compare pulmonary function before and after azithromycin therapy.

Results: Staphylococcal colonization did not significantly decrease after initiation of azithromycin (50% versus 48%). Before start of therapy, 10% of patients with staphylococcal colonization had macrolide-resistant strains. Staphylococcal resistance increased to 83% in the first year; 97% in the second and 100% in the third year after initiation of azithromycin therapy (P < 0.001). Half of macrolide-resistant S. aureus comprised the macrolide-lincosamide-streptogramin phenotype. Percent forced expiratory volume in 1 second improved in the first year after initiation of azithromycin (mean annual change: -4.75% before versus +3.09% after initiation; P < 0.01) but decreased during the second and third years after initiation (-5.15% and -3.65%, respectively). Emergence of macrolide-resistant S. aureus was not related to pulmonary function decline.

Conclusion: Maintenance azithromycin therapy in patients with CF leads to macrolide resistance in nearly all S. aureus carriers. Pulmonary function improvement after initiation of azithromycin therapy seems to be temporary and appears not to be related to macrolide resistance of S. aureus.

(C) 2007 Lippincott Williams & Wilkins, Inc.
 
L

Lastar1

New member
Just wanted to post this article here. You may want to discuss this with you doctor. This study found that in patients with staph A who were put on Zithro the Staph A became MRSA in 100% of patients.

I understand the frustration with the sinus problems. My son also cultures Staph A in his sinus and even after sinus surgery he keeps having flare-ups.

Take Care,

Lisa, mom to 7 yr old w/cf

Maintenance Azithromycin Treatment in Pediatric Patients With Cystic Fibrosis: Long-Term Outcomes Related to Macrolide Resistance and Pulmonary Function.

Original Studies

Pediatric Infectious Disease Journal. 26(1):8-12, January 2007.
Tramper-Stranders, Gerdien A. MD *; Wolfs, Tom F. W. MD, PhD +; Fleer, Andre MD, PhD ++; Kimpen, Jan L. L. MD, PhD +; van der Ent, Cornelis K. MD, PhD *
Abstract:
Background: Maintenance azithromycin therapy may improve pulmonary function in patients with cystic fibrosis (CF) with Pseudomonas aeruginosa infection because of its antiinflammatory properties. However, azithromycin therapy might increase macrolide resistance in Staphylococcus aureus cultured from respiratory secretions. We studied the emergence of macrolide resistance in S. aureus and correlated this to pulmonary function decline in pediatric patients with CF on daily azithromycin therapy.

Methods: Respiratory cultures of 100 patients with CF were analyzed for S. aureus colonization and its resistance pattern before and during 3 years after initiation of azithromycin maintenance therapy. Mean annual change in forced expiratory volume as percent of predicted (FEV1 %) was calculated to compare pulmonary function before and after azithromycin therapy.

Results: Staphylococcal colonization did not significantly decrease after initiation of azithromycin (50% versus 48%). Before start of therapy, 10% of patients with staphylococcal colonization had macrolide-resistant strains. Staphylococcal resistance increased to 83% in the first year; 97% in the second and 100% in the third year after initiation of azithromycin therapy (P < 0.001). Half of macrolide-resistant S. aureus comprised the macrolide-lincosamide-streptogramin phenotype. Percent forced expiratory volume in 1 second improved in the first year after initiation of azithromycin (mean annual change: -4.75% before versus +3.09% after initiation; P < 0.01) but decreased during the second and third years after initiation (-5.15% and -3.65%, respectively). Emergence of macrolide-resistant S. aureus was not related to pulmonary function decline.

Conclusion: Maintenance azithromycin therapy in patients with CF leads to macrolide resistance in nearly all S. aureus carriers. Pulmonary function improvement after initiation of azithromycin therapy seems to be temporary and appears not to be related to macrolide resistance of S. aureus.

(C) 2007 Lippincott Williams & Wilkins, Inc.
 
L

Lastar1

New member
Just wanted to post this article here. You may want to discuss this with you doctor. This study found that in patients with staph A who were put on Zithro the Staph A became MRSA in 100% of patients.
<br />
<br />I understand the frustration with the sinus problems. My son also cultures Staph A in his sinus and even after sinus surgery he keeps having flare-ups.
<br />
<br />Take Care,
<br />
<br />Lisa, mom to 7 yr old w/cf
<br />
<br />Maintenance Azithromycin Treatment in Pediatric Patients With Cystic Fibrosis: Long-Term Outcomes Related to Macrolide Resistance and Pulmonary Function.
<br />
<br />Original Studies
<br />
<br />Pediatric Infectious Disease Journal. 26(1):8-12, January 2007.
<br />Tramper-Stranders, Gerdien A. MD *; Wolfs, Tom F. W. MD, PhD +; Fleer, Andre MD, PhD ++; Kimpen, Jan L. L. MD, PhD +; van der Ent, Cornelis K. MD, PhD *
<br />Abstract:
<br />Background: Maintenance azithromycin therapy may improve pulmonary function in patients with cystic fibrosis (CF) with Pseudomonas aeruginosa infection because of its antiinflammatory properties. However, azithromycin therapy might increase macrolide resistance in Staphylococcus aureus cultured from respiratory secretions. We studied the emergence of macrolide resistance in S. aureus and correlated this to pulmonary function decline in pediatric patients with CF on daily azithromycin therapy.
<br />
<br />Methods: Respiratory cultures of 100 patients with CF were analyzed for S. aureus colonization and its resistance pattern before and during 3 years after initiation of azithromycin maintenance therapy. Mean annual change in forced expiratory volume as percent of predicted (FEV1 %) was calculated to compare pulmonary function before and after azithromycin therapy.
<br />
<br />Results: Staphylococcal colonization did not significantly decrease after initiation of azithromycin (50% versus 48%). Before start of therapy, 10% of patients with staphylococcal colonization had macrolide-resistant strains. Staphylococcal resistance increased to 83% in the first year; 97% in the second and 100% in the third year after initiation of azithromycin therapy (P < 0.001). Half of macrolide-resistant S. aureus comprised the macrolide-lincosamide-streptogramin phenotype. Percent forced expiratory volume in 1 second improved in the first year after initiation of azithromycin (mean annual change: -4.75% before versus +3.09% after initiation; P < 0.01) but decreased during the second and third years after initiation (-5.15% and -3.65%, respectively). Emergence of macrolide-resistant S. aureus was not related to pulmonary function decline.
<br />
<br />Conclusion: Maintenance azithromycin therapy in patients with CF leads to macrolide resistance in nearly all S. aureus carriers. Pulmonary function improvement after initiation of azithromycin therapy seems to be temporary and appears not to be related to macrolide resistance of S. aureus.
<br />
<br />(C) 2007 Lippincott Williams & Wilkins, Inc.
<br />
<br />
<br />
<br />
<br />
 
D

dramamama

New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>Lastar1</b></i>

Just wanted to post this article here. You may want to discuss this with you doctor. This study found that in patients with staph A who were put on Zithro the Staph A became MRSA in 100% of patients. .</end quote></div>

Just wanted to clear this up. This article does NOT say that Zithro causes MRSA. It causes macrolide resistance in the staph cultured in from lungs. Macrolides are the class of antibiotics that include zithromax, biaxin, etc.

MRSA is a COMPLETELY DIFFERENT staph resistant to methicillin antibiotics. This is the type of staph you hear about on the news....not staph resistant to macrolides. Although, there is no question that antibiotic resistance of all kinds is a huge problem,

While I am not a proponent of antibiotics for maintenence, Zithro is worth the risk in my opinion. It has a unique way of treating infection... It does so by controlling neutrophilic inflammation...the main type of inflammation that destroys cf airways. It is also a PROVEN gamma interferon inducer which is the chemical in the body which helps keep our Th1 immune response turned on..CFERS are notoriously low in gamma interferon. Pseudomonas actually produces a chemical that degrades gamma interferon which further compromises our immune systems. Gamma Interferon is our BIGGEST immune modulator when it comes to infection. Cfers who do NOT culture pseudo almost always have strong Th1 immune response whereas those of us who do culture pseudo and have more lung damage experience a Th2 immune response.... That is to say, inflammation with no purpose in fighting infection. When people have stronger Th2 immune response they suffer from more allergies, infection etc...

Zithromax is an immune modulator. That is to say is turns the tables on immune response in cf for the better. Due to this mechanism, it prevents quorum sensing in pseudo which limits virulence, biofilm formation and offers some in vivo killing of pseudo in cf.

If you are not comfortable with giving this drug for whatever reason, NAC and glutathione also control neutrophilic inflammation and do not cause antibiotic resistance. Glutathione also induces gamma interferon<img src="i/expressions/face-icon-small-smile.gif" border="0">
 
D

dramamama

New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>Lastar1</b></i>

Just wanted to post this article here. You may want to discuss this with you doctor. This study found that in patients with staph A who were put on Zithro the Staph A became MRSA in 100% of patients. .</end quote></div>

Just wanted to clear this up. This article does NOT say that Zithro causes MRSA. It causes macrolide resistance in the staph cultured in from lungs. Macrolides are the class of antibiotics that include zithromax, biaxin, etc.

MRSA is a COMPLETELY DIFFERENT staph resistant to methicillin antibiotics. This is the type of staph you hear about on the news....not staph resistant to macrolides. Although, there is no question that antibiotic resistance of all kinds is a huge problem,

While I am not a proponent of antibiotics for maintenence, Zithro is worth the risk in my opinion. It has a unique way of treating infection... It does so by controlling neutrophilic inflammation...the main type of inflammation that destroys cf airways. It is also a PROVEN gamma interferon inducer which is the chemical in the body which helps keep our Th1 immune response turned on..CFERS are notoriously low in gamma interferon. Pseudomonas actually produces a chemical that degrades gamma interferon which further compromises our immune systems. Gamma Interferon is our BIGGEST immune modulator when it comes to infection. Cfers who do NOT culture pseudo almost always have strong Th1 immune response whereas those of us who do culture pseudo and have more lung damage experience a Th2 immune response.... That is to say, inflammation with no purpose in fighting infection. When people have stronger Th2 immune response they suffer from more allergies, infection etc...

Zithromax is an immune modulator. That is to say is turns the tables on immune response in cf for the better. Due to this mechanism, it prevents quorum sensing in pseudo which limits virulence, biofilm formation and offers some in vivo killing of pseudo in cf.

If you are not comfortable with giving this drug for whatever reason, NAC and glutathione also control neutrophilic inflammation and do not cause antibiotic resistance. Glutathione also induces gamma interferon<img src="i/expressions/face-icon-small-smile.gif" border="0">
 
D

dramamama

New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>Lastar1</b></i>

Just wanted to post this article here. You may want to discuss this with you doctor. This study found that in patients with staph A who were put on Zithro the Staph A became MRSA in 100% of patients. .</end quote></div>

Just wanted to clear this up. This article does NOT say that Zithro causes MRSA. It causes macrolide resistance in the staph cultured in from lungs. Macrolides are the class of antibiotics that include zithromax, biaxin, etc.

MRSA is a COMPLETELY DIFFERENT staph resistant to methicillin antibiotics. This is the type of staph you hear about on the news....not staph resistant to macrolides. Although, there is no question that antibiotic resistance of all kinds is a huge problem,

While I am not a proponent of antibiotics for maintenence, Zithro is worth the risk in my opinion. It has a unique way of treating infection... It does so by controlling neutrophilic inflammation...the main type of inflammation that destroys cf airways. It is also a PROVEN gamma interferon inducer which is the chemical in the body which helps keep our Th1 immune response turned on..CFERS are notoriously low in gamma interferon. Pseudomonas actually produces a chemical that degrades gamma interferon which further compromises our immune systems. Gamma Interferon is our BIGGEST immune modulator when it comes to infection. Cfers who do NOT culture pseudo almost always have strong Th1 immune response whereas those of us who do culture pseudo and have more lung damage experience a Th2 immune response.... That is to say, inflammation with no purpose in fighting infection. When people have stronger Th2 immune response they suffer from more allergies, infection etc...

Zithromax is an immune modulator. That is to say is turns the tables on immune response in cf for the better. Due to this mechanism, it prevents quorum sensing in pseudo which limits virulence, biofilm formation and offers some in vivo killing of pseudo in cf.

If you are not comfortable with giving this drug for whatever reason, NAC and glutathione also control neutrophilic inflammation and do not cause antibiotic resistance. Glutathione also induces gamma interferon<img src="i/expressions/face-icon-small-smile.gif" border="0">
 
D

dramamama

New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>Lastar1</b></i>

Just wanted to post this article here. You may want to discuss this with you doctor. This study found that in patients with staph A who were put on Zithro the Staph A became MRSA in 100% of patients. .</end quote>

Just wanted to clear this up. This article does NOT say that Zithro causes MRSA. It causes macrolide resistance in the staph cultured in from lungs. Macrolides are the class of antibiotics that include zithromax, biaxin, etc.

MRSA is a COMPLETELY DIFFERENT staph resistant to methicillin antibiotics. This is the type of staph you hear about on the news....not staph resistant to macrolides. Although, there is no question that antibiotic resistance of all kinds is a huge problem,

While I am not a proponent of antibiotics for maintenence, Zithro is worth the risk in my opinion. It has a unique way of treating infection... It does so by controlling neutrophilic inflammation...the main type of inflammation that destroys cf airways. It is also a PROVEN gamma interferon inducer which is the chemical in the body which helps keep our Th1 immune response turned on..CFERS are notoriously low in gamma interferon. Pseudomonas actually produces a chemical that degrades gamma interferon which further compromises our immune systems. Gamma Interferon is our BIGGEST immune modulator when it comes to infection. Cfers who do NOT culture pseudo almost always have strong Th1 immune response whereas those of us who do culture pseudo and have more lung damage experience a Th2 immune response.... That is to say, inflammation with no purpose in fighting infection. When people have stronger Th2 immune response they suffer from more allergies, infection etc...

Zithromax is an immune modulator. That is to say is turns the tables on immune response in cf for the better. Due to this mechanism, it prevents quorum sensing in pseudo which limits virulence, biofilm formation and offers some in vivo killing of pseudo in cf.

If you are not comfortable with giving this drug for whatever reason, NAC and glutathione also control neutrophilic inflammation and do not cause antibiotic resistance. Glutathione also induces gamma interferon<img src="i/expressions/face-icon-small-smile.gif" border="0">
 
D

dramamama

New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>Lastar1</b></i>
<br />
<br />Just wanted to post this article here. You may want to discuss this with you doctor. This study found that in patients with staph A who were put on Zithro the Staph A became MRSA in 100% of patients. .</end quote>
<br />
<br />Just wanted to clear this up. This article does NOT say that Zithro causes MRSA. It causes macrolide resistance in the staph cultured in from lungs. Macrolides are the class of antibiotics that include zithromax, biaxin, etc.
<br />
<br />MRSA is a COMPLETELY DIFFERENT staph resistant to methicillin antibiotics. This is the type of staph you hear about on the news....not staph resistant to macrolides. Although, there is no question that antibiotic resistance of all kinds is a huge problem,
<br />
<br />While I am not a proponent of antibiotics for maintenence, Zithro is worth the risk in my opinion. It has a unique way of treating infection... It does so by controlling neutrophilic inflammation...the main type of inflammation that destroys cf airways. It is also a PROVEN gamma interferon inducer which is the chemical in the body which helps keep our Th1 immune response turned on..CFERS are notoriously low in gamma interferon. Pseudomonas actually produces a chemical that degrades gamma interferon which further compromises our immune systems. Gamma Interferon is our BIGGEST immune modulator when it comes to infection. Cfers who do NOT culture pseudo almost always have strong Th1 immune response whereas those of us who do culture pseudo and have more lung damage experience a Th2 immune response.... That is to say, inflammation with no purpose in fighting infection. When people have stronger Th2 immune response they suffer from more allergies, infection etc...
<br />
<br />Zithromax is an immune modulator. That is to say is turns the tables on immune response in cf for the better. Due to this mechanism, it prevents quorum sensing in pseudo which limits virulence, biofilm formation and offers some in vivo killing of pseudo in cf.
<br />
<br />If you are not comfortable with giving this drug for whatever reason, NAC and glutathione also control neutrophilic inflammation and do not cause antibiotic resistance. Glutathione also induces gamma interferon<img src="i/expressions/face-icon-small-smile.gif" border="0">
<br />
<br />
<br />
 
You must log in or register to reply here.
Top